StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30461% above fair value
$95.11+0.88 (+0.93%)

Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –

Kiniksa Pharmaceuticals International profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Kiniksa Pharmaceuticals International's profit margin for the twelve months ending Sep 30, 2026 was 11.6%. For fiscal 2025 it was 8.7%, against -10.2% the year before. The highest annual figure on record is 83.3% in fiscal 2022.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 20258.7%+18.9
FY2024Dec 31, 2024-10.2%−15.4
FY2023Dec 31, 20235.2%−78.1
FY2022Dec 31, 202283.3%+493.0
FY2021Dec 31, 2021-409.7%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202616.6%+6.4
Q2 FY2026Jun 30, 202610.4%−0.9
Q1 FY2026Mar 31, 202610.5%+4.3
Q4 FY2025Dec 31, 20257.0%+14.3
Q3 FY2025Sep 30, 202510.2%+21.5
Q2 FY2025Jun 30, 202511.4%+15.0
Q1 FY2025Mar 31, 20256.2%+28.4
Q4 FY2024Dec 31, 2024-7.3%−37.5
Q3 FY2024Sep 30, 2024-11.3%+9.4
Q2 FY2024Jun 30, 2024-3.6%−24.5
Q1 FY2024Mar 31, 2024-22.2%+3.2
Q4 FY2023Dec 31, 202330.3%+23.1
Q3 FY2023Sep 30, 2023-20.7%−246.7
Q2 FY2023Jun 30, 202320.9%+95.0
Q1 FY2023Mar 31, 2023-25.4%+52.9
Q4 FY2022Dec 31, 20227.2%+201.0
Q3 FY2022Sep 30, 2022226.0%+478.6
Q2 FY2022Jun 30, 2022-74.1%+465.4
Q1 FY2022Mar 31, 2022-78.3%–
Q4 FY2021Dec 31, 2021-193.8%–
Q3 FY2021Sep 30, 2021-252.5%–
Q2 FY2021Jun 30, 2021-539.5%–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?